A Photo of Professor Nianguo DONG’s Team and the Patient taken after Successful Completion of Extracorporeal Biventricular Assisted Transition Heart Transplant with the World’s Longest International Transport Distance (Doctors from Left to Right: Yang ZHAO, Huihua WANG, Nianguo DONG, Xingjian HU, Jing ZHANG and Ping LI)
The 5th Annual Conference of CHELSA, sponsored by the Extracorporeal Life Support Annual Conference of the Chinese Society of Cardiothoracic and Vascular Anesthesiology, and co-organized by the Fuwai Hospital of CAMS and Guangdong Provincial People’s Hospital, was successfully held online. Multiple Chinese leading experts in life support unfolded discussions online, winning 48,497 hits.
This Conference was joined by Professor Nianguo DONG, director of the Center for Cardiovascular Surgery and Organ Transplantation of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan (“Wuhan Union Hospital”). Professor DONG announced the delightful progress of magAssist’s extracorporeal artificial heart at the Conference： as China’s first maglev extracorporeal VAD, the device passed the preliminary review of the Clinical Ethics Committee of Wuhan Union Hospital in December 2020 and will be soon put into clinical trials.
In his report, Professor DONG gave a detailed introduction to China’s technological means in bridging heart transplant as well as the efforts in continuously improving the treatment and innovative ideas of Wuhan Union Hospital’s surgical team in the treatment of patients. According to Professor DONG, reproducing foreign technology can’t fully adapt to our national conditions, and Chinese medical workers should work to optimize the treatment strategies for patients, and provide them with more efficient, accurate and cost-effective heart transplant treatment solutions based on existing and innovative technologies.
At the end of his report, Professor DONG pointed out, “Extracorporeal VADs have few complications and are easy to manage, thus embracing a promising future!”
About Extracorporeal Artificial Hearts：
Every year, tens of thousands of patients in China die from cardiac arrest caused by explosive myocarditis, acute heart failure and traumatic accidents, such as H1N1, severe trauma, drowning, gas poisoning, myocardial infarction, and cardiogenic shock of unknown origin after thoracotomy. In patients with good lung function and in need of non-long-term circulatory support, an extracorporeal artificial heart is the most preferred transitional treatment. However, only VA-ECMO and implantable ventricular assist devices (VADs) are available clinically in China today. VA-ECMO is prone to complications, demanding in anticoagulation, and complex in management, which is not conducive to patients who need a longer stable observation period; moreover, most pulmonary blood flow is circumvented, forming a stasis area in the aortic root, which may result in ischemia or thrombus; an increased ventricular afterload is not good for cardiac function recovery; and it’s difficult to meet high flow requirements of patients. Implantable VADs are invasive and expensive, and are more suitable for patients with end-stage heart failure who require a long waiting period for transplantation (>6 months) or are not suitable for transplantation.
Therefore, an extracorporeal artificial heart can be a life-saving emergency treatment and treatment measure for these patients.
On the basis of the full-maglev drive in combination with the latest computational fluid dynamics technology， the extracorporeal artificial heart developed by magAssist has brought patients with acute heart failure and cardiogenic shock more cost-effective, flexible and stable transitional mechanical circulatory support with blood compatibility comparable to the international golden standard.